Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Adiso , a Morningside Company, to Develop Novel Immune Therapies

publication date: Mar 10, 2022

Adiso Therapeutics, a Concord, Mass. anti-inflammatory biotech, officially emerged from stealth mode with backing from Hong Kong's Morningside Ventures. According to Endpoints News, Morningside has already invested $60 million in the company and has another $35 million earmarked for the company's B round, which will include a syndicate of investors. Other sources said Morningside has supported Adiso so far with $35 million. To form Adiso, Morningside rolled up an US-Irish microbiome biotech, Artugen, for which it has been the sole support, and an unidentified US company specializing in neutrophils. More details....

Share this with colleagues:

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China